Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis

References

• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57.
   PubMed Web of Science ®Google Scholar
• Holanda NCP, Carvalho NC, Egito K, et al. Osteoporose: Epidemiologia, Classificação e Diagnóstico. In: Bandeira F, et al., editors. Endocrinologia e diabetes. Rio de Janeiro-RJ, Brazil: Medbook; 2015.
   Google Scholar
• Looker AC, Orwoll ES, Johnston CC Jr., et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–1768.
   PubMed Web of Science ®Google Scholar
• Cianferotti L, D’Asta F, Brandi ML. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2013;5:127–139.
   PubMedGoogle Scholar
• Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–170.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2010;25:2267–2294.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29:1929–1937.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57:423–428.
   PubMed Web of Science ®Google Scholar
• Hamdy RC, Daley DN. Oral calcitonin. Int J Womens Health. 2012;4:471–479.
   PubMedGoogle Scholar
• McClung MR. Emerging therapies for osteoporosis. Endocrinol Metab (Seoul). 2015;30:429–435.
   PubMedGoogle Scholar
• Geusens P. New insights into treatment of osteoporosis in postmenopausal women. RMD Open. 2015;1:e000051.
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Azria M, Silverman S, et al. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int. 2008;19:479–491.
   PubMed Web of Science ®Google Scholar
• Lazaretti-Castro M, Bianco AC. Fisiologia do metabolismo osteomineral. In: Aires MM, editor. Fisiologia. Rio de Janeiro - RJ, Brazil: Guanabara Koogan; 2012.
   Google Scholar
• Lima JG, Nobrega LHC, Mendonca RP, et al. Metabolismo osseo e mineral. In: Bandeira F, editors. Endocrinologia e diabetes. Rio de Janeiro-RJ, Brazil: Medbook; 2015.
   Google Scholar
• Hysing J, Gordeladze JO, Christensen G, et al. Renal uptake and degradation of trapped-label calcitonin. Biochem Pharmacol. 1991;41:1119–1126.
   PubMed Web of Science ®Google Scholar
• Humphreys MH, Lin SY. Peptide hormones and the regulation of sodium excretion. Hypertension. 1988;11:397–410.
   PubMed Web of Science ®Google Scholar
• Wales NA, Barrett AL. Depression of sodium, chloride and calcium ions in the plasma of goldfish (Carassius auratus) and immature freshwater- and seawater-adapted eels (Anguilla anguilla L.) after acute administration of salmon calcitonin. J Endocrinol. 1983;98:257–261.
   PubMed Web of Science ®Google Scholar
• Maricic MJ. Oral calcitonin. Curr Osteoporos Rep. 2012;10:80–85.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Bay-Jensen AC, et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol. 2011;51:460–471.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration, Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee. Calcitonin salmon for the treatment of postmenopausal osteoporosis. 2013. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm343748.pdf.
   Google Scholar
• Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Bmj. 1992;305:1124–1128.
   PubMed Web of Science ®Google Scholar
• Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int. 1986;38:3–8.
   PubMed Web of Science ®Google Scholar
• Meschia M, Brincat M, Barbacini P, et al. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 1992;47:53–57.
   PubMed Web of Science ®Google Scholar
• Grant M, Leone-Bay A. Peptide therapeutics: it’s all in the delivery. Ther Deliv. 2012;3:981–996.
   PubMedGoogle Scholar
• Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules. 2009;14:3754–3779.
   PubMed Web of Science ®Google Scholar
• Chesnut CH Iii, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med. 2000;109:267–276.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Riis BJ, et al. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol. 2008;8:12.
   PubMedGoogle Scholar
• Chesnut CH 3rd, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res. 2005;20:1548–1561.
   PubMed Web of Science ®Google Scholar
• Altman RD, Collins-Yudiskas B. Synthetic human calcitonin in refractory Paget’s disease of bone. Arch Intern Med. 1987;147:1305–1308.
   PubMed Web of Science ®Google Scholar
• Quatraro A, Minei A, De Rosa N, et al. Calcitonin in painful diabetic neuropathy. Lancet. 1992;339:746–747.
   PubMed Web of Science ®Google Scholar
• Zieleniewski W. Calcitonin nasal spray for painful diabetic neuropathy. Lancet. 1990;336:449.
   PubMed Web of Science ®Google Scholar
• Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int. 2012;23:17–38.
   PubMed Web of Science ®Google Scholar
• Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl. 1997;275:112–114.
   PubMedGoogle Scholar
• Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989;11:205–209.
   PubMed Web of Science ®Google Scholar
• Leone-Bay A, McInnes C, Wang N, et al. Microsphere formation in a series of derivatized alpha-amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin. J Med Chem. 1995;38:4257–4262.
   PubMed Web of Science ®Google Scholar
• Leone-Bay A, Santiago N, Achan D, et al. N-acylated alpha-amino acids as novel oral delivery agents for proteins. J Med Chem. 1995;38:4263–4269.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Alexandersen P, et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage. 2015;23:532–543.
   PubMed Web of Science ®Google Scholar
• Malkov D, Angelo R, Wang HZ, et al. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005;2:191–197.
   PubMedGoogle Scholar
• Buclin T, Cosma Rochat M, Burckhardt P, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002;17:1478–1485.
   PubMed Web of Science ®Google Scholar
• Binkley N, Bolognese M, Sidorowicz-Bialynicka A, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27:1821–1829.
   PubMed Web of Science ®Google Scholar
• Maher S, Ryan B, Duffy A, et al. Formulation strategies to improve oral peptide delivery. Pharm Pat Anal. 2014;3:313–336.
   PubMedGoogle Scholar
• Karsdal MA, Byrjalsen I, Riis BJ, et al. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin Pharmacol. 2008;8:5.
   PubMedGoogle Scholar
• Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage. 2010;18:150–159.
   PubMed Web of Science ®Google Scholar
• Binkley N, Bone H, Gilligan JP, et al. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos Int. 2014;25:2649–2656.
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004;19:1531–1538.
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425–430.
   PubMed Web of Science ®Google Scholar
• Russo LA, Lau E, Tang H, et al. Efficacy and safety of oral salmon calcitonin in postmenopausal osteoporosis: randomized, double-blind, placebo-controlled trial. ASBMR 2010 annual meeting abstract MO0408. J Bone Miner Res. 2010;25:S480.
   Google Scholar
• Karsdal MA, Byrjalsen I, Henriksen K, et al. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J Clin Pharmacol. 2009;49:229–234.
   PubMed Web of Science ®Google Scholar
• Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31:57–61.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Henriksen K, et al. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol. 2010;66:29–37.
   PubMed Web of Science ®Google Scholar
• Rosenthal D, et al. Hormônios: Classificação, Síntese, Transporte e Mecanismo de Ação. In: Bandeira F, editors. Endocrinologia e diabetes. Rio de Janeiro-RJ, Brazil: Medbook; 2015.
   Google Scholar
• Meschia M, Brincat M, Barbacini P, et al. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int. 1993;53:17–20.
   PubMed Web of Science ®Google Scholar
• Szucs J, Horvath C, Kollin E, et al. Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcif Tissue Int. 1992;50:7–10.
   PubMed Web of Science ®Google Scholar
• Hongo M, Miyakoshi N, Kasukawa Y, et al. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Metab. 2015;33:432–439.
   PubMed Web of Science ®Google Scholar
• Takakuwa M, Iwamoto J. Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. Biol Pharm Bull. 2012;35:1159–1165.
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest. 1993;91:1138–1148.
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Steer BM, Fraher LJ, et al. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 1991;14:67–83.
   PubMedGoogle Scholar
• Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205–3211.
   PubMed Web of Science ®Google Scholar
• Feigh M, Henriksen K, Andreassen KV, et al. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes Obes Metab. 2011;13:911–920.
   PubMed Web of Science ®Google Scholar
• Feigh M, Nielsen RH, Hansen C, et al. Oral salmon calcitonin improves fasting and postprandial glycemic control in lean healthy rats. Horm Metab Res. 2012;44:130–134.
   PubMed Web of Science ®Google Scholar
• Feigh M, Hjuler ST, Andreassen KV, et al. Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats. Eur J Pharmacol. 2014;737:91–96.
   PubMed Web of Science ®Google Scholar
• Feigh M, Andreassen KV, Hjuler ST, et al. Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats. Menopause. 2013;20:785–794.
   PubMed Web of Science ®Google Scholar
• Emisphere - Salmon Calcitonin for Osteoarthritis and Osteoporosis. [cited 2016 Mar 11]. Available from: http://www.emisphere.com/salmon_calcitonin.html.
   Google Scholar
• Wells G, Chernoff J, Gilligan JP, et al. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos Int. 2016;27:13–19.
   PubMed Web of Science ®Google Scholar
• Sun LM, Lin MC, Muo CH, et al. Calcitonin nasal spray and increased cancer risk: a population-based nested case-control study. J Clin Endocrinol Metab. 2014;99:4259–4264.
   PubMed Web of Science ®Google Scholar
• Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer. 2005;117:281–288.
   PubMed Web of Science ®Google Scholar
• Hill AB. The environment and disease: association or causation? 1965. J R Soc Med. 2015;108:32–37.
   PubMed Web of Science ®Google Scholar
• Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013;47:1675–1684.
   PubMed Web of Science ®Google Scholar
• In brief: cancer risk with salmon calcitonin. Med Lett Drugs Ther. 2013;55:29.
   Web of Science ®Google Scholar